Quantum Computing partners with INmune Bio to apply quantum optimization, AI in Alzheimer’s drug research

Quantum Computing entered a collaboration with INmune Bio to apply quantum optimization, AI, and analytics to Alzheimer’s drug research. Work will use QCi’s Dirac-3S quantum optimization machine to identify new indications and biomarkers for INmune Bio’s XPro (XPro1595). Project will analyze INmune Bio clinical-trial data alongside public biomedical datasets to prioritize patient groups and potential disease targets. Engagement is QCi’s first commercial customer deal in pharma and biotech, expanding its quantum computing applications into drug development. Program will benchmark quantum optimization results against conventional statistical and machine-learning methods to assess where quantum adds value. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quantum Computing Inc. published the original content used to generate this news brief via (Ref. ID: 202610140830PR_NEWS_USPR_____PH71752) on October 14, 2026, and is solely resp